Literature DB >> 11295986

Stroke prevention and treatment in sickle cell disease.

R J Adams1.   

Abstract

While the problem of stroke in the patients with sickle cell disease (SCD) has been known for more than 75 years, adequate preventive and treatment strategies are just now being tested. Recent data on prevalence and incidence have been obtained from the Cooperative Study of Sickle Cell Disease of more than 4000 patients with SCD observed in 23 US clinical centers over a 10-year period.1 The overall age-specific incidence of first stroke in SCD (homozygous sickle cell anemia) is low (0.13%) at ages younger than 24 months, increasing to just over 1% at ages 2 to 5 years, with only a slight decrement to 0.79% at ages 6 to 9 years. The risk of brain infarction declines until a second peak is seen at ages older than 50 years, when the incidence again increases to nearly 1.3%. Although intracranial hemorrhage does occur in young children with SCD, the risk is low compared with older children and adults. The Cooperative Study of Sickle Cell Disease reported risk factors for infarction to be prior transient ischemic attack, low steady-state hemoglobin values, and rate and recency of episodes of acute chest syndrome, as well as elevated systolic blood pressure. Risk factors for intracranial hemorrhage included low steady-state hemoglobin values and a high leukocyte count. The burden of cerebrovascular disease is even higher if subclinical magnetic resonance imaging (MRI) lesions, presumed to be ischemic, are included. The prevalence of such lesions is more than 22% in patients with SCD, and most of these patients have not reported symptoms, although specialized neuropsychological testing shows lower scores in children with silent lesions on MRI scans. Patients with a history of clinical stroke typically have infarcts in the cortex and deep white matter, whereas silent infarcts tend to be more limited to deep white matter. Common infarction patterns are characterized by wedge-shaped lesions of large-vessel territories; border zone infarctions, particularly of the middle and cerebral artery watershed region; and small punctate lesions of the deep white matter. Fat embolism to the brain and venous thromboses are encountered rarely.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295986     DOI: 10.1001/archneur.58.4.565

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  14 in total

1.  Erythrocytapheresis: Do Not Forget a Useful Therapy!

Authors:  Heidrun Ullrich; Roland Fischer; Regine Grosse; Uwe Kordes; Claudia Schubert; Bettina Altstadt; Georges Andreu
Journal:  Transfus Med Hemother       Date:  2008-01-15       Impact factor: 3.747

Review 2.  Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.

Authors:  Junaid Ansari; Youmna E Moufarrej; Rafal Pawlinski; Felicity N E Gavins
Journal:  Expert Rev Hematol       Date:  2017-12-05       Impact factor: 2.929

Review 3.  [Rare causes of stroke-a frequent stroke etiology].

Authors:  Antje Schmidt-Pogoda; Jens Minnerup
Journal:  Nervenarzt       Date:  2019-10       Impact factor: 1.214

4.  Stroke in sickle cell disease in Africa: case report.

Authors:  J Makani
Journal:  East Afr Med J       Date:  2004-12

Review 5.  Treatment of acute ischemic stroke: beyond thrombolysis and supportive care.

Authors:  Neelofer Shafi; Scott E Kasner
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

6.  Treatment and prevention of cerebrovascular disorders in children.

Authors:  John Kylan Lynch; Steven Pavlakis; Gabrielle Deveber
Journal:  Curr Treat Options Neurol       Date:  2005-11       Impact factor: 3.598

Review 7.  Diagnosis and treatment of ischemic pediatric stroke.

Authors:  Donald P Younkin
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

8.  Association Between Periodic Limb Movements in Sleep and Cerebrovascular Changes in Children With Sickle Cell Disease.

Authors:  Jenny Lin; Kerry Morrone; Deepa Manwani; Rina Chernin; Ellen J Silver; Keivan Shifteh; Sanghun Sin; Raanan Arens; Katharina Graw-Panzer
Journal:  J Clin Sleep Med       Date:  2019-07-15       Impact factor: 4.062

9.  Silent Cerebral Infarct Transfusion (SIT) trial imaging core: application of novel imaging information technology for rapid and central review of MRI of the brain.

Authors:  Bruce A Vendt; Robert C McKinstry; William S Ball; Michael A Kraut; Fred W Prior; Bruce Barton; James F Casella; Michael R DeBaun
Journal:  J Digit Imaging       Date:  2008-04-09       Impact factor: 4.056

Review 10.  Cerebrovascular disorders in children.

Authors:  John Kylan Lynch
Journal:  Curr Neurol Neurosci Rep       Date:  2004-03       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.